Filtered By:
Specialty: Cardiology
Nutrition: Sodium
This page shows you your search results in order of relevance. This is page number 9.
Order by Relevance | Date
Total 159 results found since Jan 2013.
Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-Of-The-Art Review
Cardiovasc Hematol Agents Med Chem. 2021 Aug 9. doi: 10.2174/1871525719666210809121016. Online ahead of print.ABSTRACTSodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of anti-diabetic agents that block the reabsorption of glucose in the proximal convoluted tubule of the nephron, thereby contributing to glycosuria and lowering blood glucose levels. SGLT2 inhibitors have been associated with improved cardiovascular outcomes in patients with diabetes, including a reduced risk of cardiovascular death and hospitalizations for heart failure. Recently, DAPA-HF and EMPEROR REDUCED trials showed the beneficial cardiova...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - August 9, 2021 Category: Cardiology Authors: Mauro Gitto Dimitrios A Vrachatis Gianluigi Condorelli Konstantinos Papathanasiou Bernhard Reimers Spyridon Deftereos Giulio G Stefanini Source Type: research
Salt substitution reduces the rate of cardiovascular events and death
Nature Reviews Cardiology, Published online: 13 September 2021; doi:10.1038/s41569-021-00615-3In the SSaSS trial, substituting regular table salt (100% sodium chloride) with an alternative containing 25% potassium chloride reduced the rate of stroke, major cardiovascular events and all-cause death.
Source: Nature Reviews Cardiology - September 13, 2021 Category: Cardiology Authors: Gregory B. Lim Source Type: research
Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
AbstractSodium-glucose cotransporter-2 (SGLT2) inhibitors are new antidiabetic drugs that reduce hyperglycemia by inhibiting the glucose reabsorption in renal proximal tubules. Clinical studies have shown that SGLT2 inhibitors not only improve glycemic control but also reduce major adverse cardiovascular events (MACE, cardiovascular and total mortality, fatal or nonfatal myocardial infarction or stroke) and hospitalization for heart failure (HF), and improve outcome in chronic kidney disease. These cardiovascular and renal benefits have now been confirmed in both diabetes and non-diabetes patients. The precise mechanism(s)...
Source: Cardiovascular Drugs and Therapy - November 10, 2021 Category: Cardiology Source Type: research
Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction
CONCLUSION: Sodium ozagrel with atorvastatin can reduce inflammatory reactions; regulate ESR and HMGB1, PON-1, and MIF levels; control blood glucose and lipid indexes; and alleviate nerve injury without increasing adverse effects of atorvastatin alone.PMID:35047123 | PMC:PMC8696649 | DOI:10.4239/wjd.v12.i12.2096
Source: Atherosclerosis - January 20, 2022 Category: Cardiology Authors: You Yu Lin Wang Xu Zhu Ya-Fei Liu Hai-Ying Ma Source Type: research
Beneficial cardiovascular and remodeling effects of SGLT2 inhibitors: pathophysiologic mechanisms
Expert Rev Cardiovasc Ther. 2022 Mar 23. doi: 10.1080/14779072.2022.2057949. Online ahead of print.ABSTRACTINTRODUCTION: The intent of this paper is to review the data regarding the multipotential effects of the sodium-glucose cotransporter 2 (SGLT 2) inhibitors, their cardiovascular protective effects, and their mechanism of action.AREAS COVERED: The SGLT2 inhibitors exert their beneficial antidiabetic and cardioprotective effects through increased glucose excretion from the kidneys, blood pressure and weight lowering, vasodilation and other potential beneficial effects. They have been used for the treatment of patients w...
Source: Expert Review of Cardiovascular Therapy - March 23, 2022 Category: Cardiology Authors: Steven G Chrysant George S Chrysant Source Type: research
Fabrication of Customizable Intraplaque Hemorrhage Phantoms for Magnetic Resonance Imaging
CONCLUSIONS: The cylindrical IPH phantom accurately modeled the short T1 time characteristic of methemoglobin-laden IPH, with the IPH sites exhibiting little variation in imaging properties over 31 days. Furthermore, MPRAGE images of the anatomical atherosclerosis replicas closely matched those of clinical plaques. In combination, these phantoms will allow for IPH imaging protocol standardization and thus facilitate future multicenter IPH imaging.PMID:35486294 | DOI:10.1007/s11307-022-01722-4
Source: Atherosclerosis - April 29, 2022 Category: Cardiology Authors: Matteo A Bomben Alan R Moody James M Drake Naomi Matsuura Source Type: research
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
Med (N Y). 2021 Nov 12;2(11):1203-1230. doi: 10.1016/j.medj.2021.10.004.ABSTRACTCardiovascular and renal outcome trials (CVOTs) for glucagon-like-peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) highlight new options for people with and without type 2 diabetes (T2D). Drugs within these classes reduce rates of major adverse cardiovascular events (MACE), with SGLT2i simultaneously attenuating decline in kidney function. SGLT2i reduce rates of heart failure in people with and without T2D, whereas GLP1RA lower rates of myocardial infarction and stroke in people with T2D with or withou...
Source: Atherosclerosis - May 19, 2022 Category: Cardiology Authors: David Z I Cherney Jacob A Udell Daniel J Drucker Source Type: research
Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus
Background:The differential benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1RA) in cardiovascular or renal outcomes have not been fully investigated.Methods: Patients with diabetes prescribed SGLT2i or GLP1RA were retrospectively identified. Patients treated with antihyperglycemic medications other than SGLT2i or GLP1RA were used as a control group. Primary outcomes were composite ischemic events (acute coronary syndrome, coronary revascularization, and stroke) and a composite of heart failure and renal events (hospitalization for heart failure, renal death,...
Source: International Journal of Cardiology - June 14, 2022 Category: Cardiology Authors: Chee Hae Kim, In-Chang Hwang, Hong-Mi Choi, Chang Ho Ahn, Yeonyee E. Yoon, Goo-Yeong Cho Source Type: research
Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions
Atrial fibrillation, the most common cardiac arrhythmia, results in substantial morbidity and mortality related to its increased risks of stroke, heart failure, and impaired cognitive function. The incidence a...
Source: Cardiovascular Diabetology - June 28, 2022 Category: Cardiology Authors: Syona S Shetty and Andrew Krumerman Tags: Review Source Type: research
Impaired renal function and mortalities in acute heart failure with different phenotypes
ConclusionsOn-admission IRF was independently predictive of long-term mortality in patients hospitalized for HF, irrespective of HF phenotypes. Furthermore, IRF was also associated with short-term mortality in HFrEF and HFmrEF, but not in HFpEF.
Source: ESC Heart Failure - June 17, 2022 Category: Cardiology Authors: Wei ‐Ming Huang,
Hao‐Chih Chang,
Ching‐Wei Lee,
Chi‐Jung Huang,
Wen‐Chung Yu,
Hao‐Min Cheng,
Chao‐Yu Guo,
Chern‐En Chiang,
Chen‐Huan Chen,
Shih‐Hsien Sung Tags: Original Article Source Type: research
Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to lower cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risks. Here, we aimed to evaluate the effect of SGLT2 inhibitors on major adverse cardiovascular events (MACE), a composite of cardiovascular mortality, myocardial infarction, or ischemic stroke and hospitalization for heart failure in patients with T2DM and atrial fibrillation (AF). Using the Korean National Health Insurance Service database, we identified 40,268 patients with T2DM and AF who were newly prescribed oral hypoglycemic drugs ...
Source: The American Journal of Cardiology - July 7, 2022 Category: Cardiology Authors: Chang Hee Kwon, Ye-Jee Kim, Min-Ju Kim, Myung-Jin Cha, Min Soo Cho, Gi-Byoung Nam, Kee-Joon Choi, Jun Kim Source Type: research
